Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
Open Access
- 28 September 2012
- journal article
- case report
- Published by Springer Nature in Diabetes Therapy
- Vol. 3 (1) , 1-9
Abstract
To examine the efficacy of sitagliptin and miglitol when added to ongoing insulin treatment in a patient with type 2 diabetes who had undergone partial gastrectomy.Keywords
This publication has 27 references indexed in Scilit:
- Comparisons of the effects of 12‐week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patientsDiabetes, Obesity and Metabolism, 2011
- Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes, 2011
- A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markersCardiovascular Diabetology, 2011
- Miglitol induces prolonged and enhanced glucagon‐like peptide‐1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patientsDiabetic Medicine, 2009
- Effect of sitagliptin, a dipeptidyl peptidase‐4 inhibitor, on beta‐cell function in patients with type 2 diabetes: a model‐based approachDiabetes, Obesity and Metabolism, 2008
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysisBMC Endocrine Disorders, 2008
- Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trialsCurrent Medical Research and Opinion, 2008
- The role of gut hormones in glucose homeostasisJournal of Clinical Investigation, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Is There a Role for ??-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?Drugs, 2003